Isofol Medical AB (publ) Stock Nasdaq Stockholm
Equities
SE0009581051
Pharmaceuticals
Sales 2021 | 22.41M 2.06M | Sales 2022 | 12.8M 1.18M | Capitalization | 120M 10.98M |
---|---|---|---|---|---|
Net income 2021 | -200M -18.38M | Net income 2022 | -160M -14.7M | EV / Sales 2021 | 49.7 x |
Net cash position 2021 | 378M 34.72M | Net cash position 2022 | 187M 17.15M | EV / Sales 2022 | -5.24 x |
P/E ratio 2021 |
-5.8
x | P/E ratio 2022 |
-0.75
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 62.57% |
Managers | Title | Age | Since |
---|---|---|---|
Petter Lindqvist
CEO | Chief Executive Officer | 72 | Jan. 08 |
Magnus Hurst
DFI | Director of Finance/CFO | 68 | Jan. 09 |
Roger Tell
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lars Erik Lind
CHM | Chairman | 83 | - |
Sten Nilsson
BRD | Director/Board Member | 76 | Jan. 03 |
Alain Herrera
BRD | Director/Board Member | 74 | 17-12-31 |
1st Jan change | Capi. | |
---|---|---|
+5.20% | 69.91B | |
+10.97% | 9.03B | |
-17.03% | 4.75B | |
+37.51% | 4.31B | |
+3.92% | 3.88B | |
+18.06% | 2.37B | |
-24.13% | 2.26B | |
-29.70% | 2.2B | |
+9.09% | 1.98B |